Dical treatment and H PARP2 moglobinwerte Before treatment were selected as potential St Rfaktoren selected Hlt. Univariate analyzes were conducted to determine the effect of these factors on time to discontinuation of therapy to assess for uterine bleeding using log-rank Cox tests.A modelsuitable for a long-term use because of its negative effects, such as bone density loss. If the high rate of recurrence of endometriosis after completion of the medical treatment is contemplated, a drug that can be used in the long run k Is to occur strongly to menopause ben Be taken, and with respect to the use of long term, several studies have demonstrated that dienogest is very promising.13 15, however, dienogest has uterine bleeding that its major adverse effects, and patients with adenomyosis are h higher risk. For the safe use of dienogest, we thought it was very important to the properties of adenomyosis patients with gr Erer likely to experience uterine bleeding and then Final criteria for the contra-indications in patients understand dienogest adenomyosis. This study showed that amounts to Chtliche number of patients with adenomyosis with dienogest discontinued treatment due to uterine bleeding. Unfortunately, ben CONFIRMS four of these patients hysterectomy for symptom My uncontrollable adenomyosis Strips, ridiculed Ngerte bleeding and / or An Chemistry that results. In contrast to our findings showed other studies that have examined the efficacy and safety of dienogest a relatively low incidence of treatment discontinuation.7, 8 This may be because these studies were not restricted Nkt on adenomyosis patients and repr Sentieren therefore no specific risk associated with building rmutter bleeding in patients with adenomyosis. This study has demonstrated the hour break Frequently the treatment for uterine bleeding may occur in patients with adenomyosis. The present study identified several risk factors for discontinuation because of uterine bleeding in patients with adenomyosis, 饦 age 8 years showed a statistically significant risk factor even after contr Of the H Moglobins before treatment. Estradiol was 60 pg / ml in the third month of treatment, a risk factor for discontinuation of treatment due to uterine bleeding after three months of treatment. Although sagittal surface is square bottle Of the building Rmutter before treatment was not statistically significantly after discontinuation of treatment for uterine bleeding context, a gr Ere trial demonstrated statistical significance. Recently, several studies have reported that Gn RH agonist treatment followed by treatment dienogest, the sequential method, the H FREQUENCY of uterine bleeding w Reduce dienogest during treatment.16 Although our study found no significance in the treatment before dienogest , a well-designed study EU focus on this relatively new method is applied to evaluate the effect of reducing the H Frequency and severity of uterine bleeding. This study has a RESTRICTIONS LIMITATION: The primary endpoint was re discontinuation of therapy due to uterine bleeding. But if discontinued treatment, is a comprehensive decision and do not necessarily reflect the final heavy menstrual bleeding. For example, our study has not the severity of the disease endometriosis or the outcome of dienoge.